161 related articles for article (PubMed ID: 11059566)
1. Cytochrome P450 isoenzyme mRNA expression pattern in human urinary bladder malignancies and normal urothelium.
Brauers A; Manegold E; Buettner R; Baron JM; Merk HF; Jakse G
Cancer Detect Prev; 2000; 24(4):356-63. PubMed ID: 11059566
[TBL] [Abstract][Full Text] [Related]
2. [Expression of cyclooxygenase-2 in human transitional cell bladder carcinomas].
Zhan J; Tang XD
Ai Zheng; 2002 Nov; 21(11):1212-6. PubMed ID: 12526218
[TBL] [Abstract][Full Text] [Related]
3. Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of bladder.
Margulis V; Shariat SF; Ashfaq R; Thompson M; Sagalowsky AI; Hsieh JT; Lotan Y
J Urol; 2007 Mar; 177(3):1163-8. PubMed ID: 17296438
[TBL] [Abstract][Full Text] [Related]
4. Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage.
Caprodossi S; Lucciarini R; Amantini C; Nabissi M; Canesin G; Ballarini P; Di Spilimbergo A; Cardarelli MA; Servi L; Mammana G; Santoni G
Eur Urol; 2008 Sep; 54(3):612-20. PubMed ID: 17977643
[TBL] [Abstract][Full Text] [Related]
5. Quantitative detection of cytokeratin 20 mRNA expression in bladder carcinoma by real-time reverse transcriptase-polymerase chain reaction.
Christoph F; Müller M; Schostak M; Soong R; Tabiti K; Miller K
Urology; 2004 Jul; 64(1):157-61. PubMed ID: 15245962
[TBL] [Abstract][Full Text] [Related]
6. Real-time quantitative analysis for human telomerase reverse transcriptase mRNA and human telomerase RNA component mRNA expressions as markers for clinicopathologic parameters in urinary bladder cancer.
Takihana Y; Tsuchida T; Fukasawa M; Araki I; Tanabe N; Takeda M
Int J Urol; 2006 Apr; 13(4):401-8. PubMed ID: 16734859
[TBL] [Abstract][Full Text] [Related]
7. [The significance of the expression of cyclooxygenase-2 in bladder transitional cell carcinoma tissues].
Ren L; Hou SK; He LF; Ye HY; Guan KP
Zhonghua Wai Ke Za Zhi; 2004 Sep; 42(18):1104-7. PubMed ID: 15498296
[TBL] [Abstract][Full Text] [Related]
8. Expression of chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) in bladder transitional cell carcinoma.
Ham WS; Lee JH; Yu HS; Choi YD
Urology; 2008 Oct; 72(4):921-6. PubMed ID: 18387660
[TBL] [Abstract][Full Text] [Related]
9. Differential mucin MUC7 gene expression in invasive bladder carcinoma in contrast to uniform MUC1 and MUC2 gene expression in both normal urothelium and bladder carcinoma.
Retz M; Lehmann J; Röder C; Plötz B; Harder J; Eggers J; Pauluschke J; Kalthoff H; Stöckle M
Cancer Res; 1998 Dec; 58(24):5662-6. PubMed ID: 9865718
[TBL] [Abstract][Full Text] [Related]
10. Expression of cyclooxygenase-2 in patients with bladder carcinoma.
Yoshimura R; Sano H; Mitsuhashi M; Kohno M; Chargui J; Wada S
J Urol; 2001 May; 165(5):1468-72. PubMed ID: 11342898
[TBL] [Abstract][Full Text] [Related]
11. Association of nucleophosmin/B23 mRNA expression with clinical outcome in patients with bladder carcinoma.
Tsui KH; Cheng AJ; Chang Pe; Pan TL; Yung BY
Urology; 2004 Oct; 64(4):839-44. PubMed ID: 15491744
[TBL] [Abstract][Full Text] [Related]
12. A prospective evaluation of the diagnostic and potential prognostic utility of urinary human telomerase reverse transcriptase mRNA in patients with bladder cancer.
Bowles L; Bialkowska-Hobrzanska H; Bukala B; Nott L; Razvi H
Can J Urol; 2004 Dec; 11(6):2438-44. PubMed ID: 15636669
[TBL] [Abstract][Full Text] [Related]
13. Reduced lecithin: retinol acyltransferase expression correlates with increased pathologic tumor stage in bladder cancer.
Boorjian S; Tickoo SK; Mongan NP; Yu H; Bok D; Rando RR; Nanus DM; Scherr DS; Gudas LJ
Clin Cancer Res; 2004 May; 10(10):3429-37. PubMed ID: 15161698
[TBL] [Abstract][Full Text] [Related]
14. Activation of RAS family genes in urothelial carcinoma.
Boulalas I; Zaravinos A; Karyotis I; Delakas D; Spandidos DA
J Urol; 2009 May; 181(5):2312-9. PubMed ID: 19303097
[TBL] [Abstract][Full Text] [Related]
15. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder.
Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A
Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521
[TBL] [Abstract][Full Text] [Related]
16. RNA expression of cytochrome P450 in breast cancer patients.
Vaclavikova R; Hubackova M; Stribrna-Sarmanova J; Kodet R; Mrhalova M; Novotny J; Gut I; Soucek P
Anticancer Res; 2007; 27(6C):4443-50. PubMed ID: 18214058
[TBL] [Abstract][Full Text] [Related]
17. Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: cytochrome p450 oxidoreductase in bladder tissues and tumors.
Li D; Gan Y; Wientjes MG; Badalament RA; Au JL
J Urol; 2001 Dec; 166(6):2500-5. PubMed ID: 11696818
[TBL] [Abstract][Full Text] [Related]
18. Transient receptor potential vanilloid type 1 (TRPV1) expression changes from normal urothelium to transitional cell carcinoma of human bladder.
Lazzeri M; Vannucchi MG; Spinelli M; Bizzoco E; Beneforti P; Turini D; Faussone-Pellegrini MS
Eur Urol; 2005 Oct; 48(4):691-8. PubMed ID: 15992990
[TBL] [Abstract][Full Text] [Related]
19. Expression of lung resistance-related protein in transitional cell carcinoma of bladder.
Zhu Y; Kong C; Zeng Y; Sun Z; Gao H
Urology; 2004 Apr; 63(4):694-8. PubMed ID: 15072883
[TBL] [Abstract][Full Text] [Related]
20. Comparisons of (+/-)-benzo[a]pyrene-trans-7,8-dihydrodiol activation by human cytochrome P450 and aldo-keto reductase enzymes: effect of redox state and expression levels.
Quinn AM; Penning TM
Chem Res Toxicol; 2008 May; 21(5):1086-94. PubMed ID: 18402469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
